Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

González Martin, A, Oza, AM, Embleton, AC et al. (13 more authors) (2019) Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecologic Oncology, 152 (1). pp. 53-60. ISSN 0090-8258

Abstract

Metadata

Authors/Creators:
  • González Martin, A
  • Oza, AM
  • Embleton, AC
  • Pfisterer, J
  • Ledermann, JA
  • Pujade-Lauraine, E
  • Kristensen, G
  • Bertrand, MA
  • Beale, P
  • Cervantes, A
  • Kent, E
  • Kaplan, RS
  • Parmar, MKB
  • Scotto, N
  • Perren, T ORCID logo https://orcid.org/0000-0001-8472-8856
  • ICON7 investigators
Copyright, Publisher and Additional Information: © 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents lists available atScienceDirectGynecologic Oncologyjournal homepage:www.elsevier.com/locate/ygyno
Keywords: Bevacizumab; Ovarian cancer; Residual disease; Cytoreductive surgery
Dates:
  • Accepted: 30 August 2018
  • Published (online): 16 November 2018
  • Published: January 2019
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
Funding Information:
FunderGrant number
MRC (Exceptions)FAISAL AL-TERKAIT
Depositing User: Symplectic Publications
Date Deposited: 11 Oct 2018 14:45
Last Modified: 15 Jan 2019 10:21
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.ygyno.2018.08.036

Share / Export

Statistics